1. Calidi Biotherapeutics Files 8-K: Material Agreement and Unregistered Equity Sale Signal Potential Capital Move
Calidi Biotherapeutics, Inc. has triggered multiple disclosure items in a new SEC 8-K filing that points to significant corporate activity. The biotech company reported both the entry into a material definitive agreement under Item 1.01 and unregistered sales of equity securities under Item 3.02, a combination that typ...